Skip to main content

Table 1 Immunohistochemical staining for the MLH1, MSH2, MSH6 and PMS2 proteins of patients P12, P14 and P16

From: Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN

Patient

MLH1

MSH2

MSH6

PMS2

Tissue

PDCO (% positive)

Tissue

PDCO (% positive)

Tissue

PDCO (% positive)

Tissue

PDCO (% positive)

P12

MSS

95

MSS

100

MSS

95

MSS

100

P14

MSS

90

MSS

100

MSS

100

MSS

70

P16

MSS

80

MSS

100

MSS

100

MSS

70

  1. Microsatellite analysis obtained for each CRC tissue section and paired PDCOs is indicated in the table. The percentage of positive cells for the MLH1, MSH2, MSH6 and PMS2 proteins in tumor PDCOs relative to total cells is represented